What is Biomesense?
Biomesense operates at the intersection of artificial intelligence and microbiome science, providing a sophisticated platform for the continuous tracking and analysis of gut health. By utilizing proprietary technologies such as GutLab and MetaBiome, the company offers high-fidelity data that is essential for biomarker discovery and clinical product development. Their market position is defined by a commitment to unlocking the therapeutic potential of the human microbiome, serving as a critical partner for scientists and pharmaceutical entities seeking to translate complex biological data into actionable health outcomes. Through its data-centric approach, Biomesense is effectively bridging the gap between raw biological information and personalized medical interventions.
How much funding has Biomesense raised?
Biomesense has raised a total of $3M across 1 funding round:
Other Financing Round
$3M
Other Financing Round (2023): $3M with participation from Harvest Ridge Capital, Bluestein Ventures, and SOSV
Key Investors in Biomesense
Harvest Ridge Capital
Harvest Ridge Capital is an investment firm that provides strategic backing to high-growth companies, focusing on long-term value creation and market expansion.
Bluestein Ventures
Bluestein Ventures is a venture capital firm focused on investing in early-stage, game-changing ventures within the food industry, emphasizing active partnership and product-market fit.
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
What's next for Biomesense?
With the support of this major enterprise-level funding, Biomesense is poised to transition into a phase of rapid commercial expansion and technological refinement. The strategic roadmap likely involves enhancing the scalability of its MetaBiome platform to accommodate larger clinical datasets and fostering deeper collaborations with global research institutions. As the company matures, the focus will shift toward validating its biomarkers in broader patient populations, thereby solidifying its role as an indispensable infrastructure provider in the precision medicine ecosystem. Investors are closely monitoring the firm's ability to convert its robust data pipeline into standardized clinical tools that can influence long-term patient health trajectories.
See full Biomesense company page
